TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32515412

Group type: EXPERIMENTAL
Intervention: Oral counseling (OR) and the use of an application (App) for smartphones
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: OR without the app
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Video (VD) and app
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: VD without app
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Use of technology (VD and/or App)
Number of subjects: 291

Group type: COMPARATOR
Intervention: Non‐use of technology (OR alone)
Number of subjects: 291
Study: 35317705

Group type: EXPERIMENTAL
Intervention: Progressive minimal changes to both first and second implants over a period of nine months to achieve balanced dynamic ranges.
Number of subjects: 19

Group type: COMPARATOR
Intervention: Changes to their sequential implant only (Control group).
Number of subjects: 19
Study: 34474581

Group type: EXPERIMENTAL
Intervention: Trunk-oriented exercise program
Number of subjects: 26

Group type: COMPARATOR
Intervention: Conventional exercise program
Number of subjects: 26
Study: 34043719

Group type: EXPERIMENTAL
Intervention: Brazilian propolis (5 tablets daily, 508.5 mg of propolis)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (5 tablets daily)
Number of subjects: 80
Study: 32408011

Group type: EXPERIMENTAL
Intervention: Hot adenoidectomy (n=30)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Cold adenoidectomy (n=28)
Number of subjects: 58
Study: 35072714

Group type: EXPERIMENTAL
Intervention: Take a Break (TAB) intervention with gamification and NRT sampling
Number of subjects: 433

Group type: COMPARATOR
Intervention: NRT sampling only (comparison group)
Number of subjects: 433
Study: 33634382

Group type: EXPERIMENTAL
Intervention: Eighteen‐month weight loss intervention
Number of subjects: 278
Study: 34253599

Group type: EXPERIMENTAL
Intervention: Community monitoring program with training and incentives for patrolling
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (communities not receiving the program)
Number of subjects: 39
Study: 34098821

Group type: EXPERIMENTAL
Intervention: 8-week intervention to teach resourcefulness plus routine health education
Number of subjects: 72

Group type: COMPARATOR
Intervention: Routine health education only
Number of subjects: 72
Study: 33012589

Group type: EXPERIMENTAL
Intervention: WhisperFlow CPAP
Number of subjects: 140

Group type: COMPARATOR
Intervention: High Flow Nasal Cannula (HFNC)
Number of subjects: 140
Study: 36383473

Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Virtual reality
Number of subjects: 343

Group type: COMPARATOR
Intervention: Control
Number of subjects: 343
Study: 34018919

Group type: EXPERIMENTAL
Intervention: VIPP-SD plus usual care
Number of subjects: 300

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 300
Study: 35917763

Group type: EXPERIMENTAL
Intervention: ST+ABR (cognitive-behavioral therapy for smoking cessation and approach bias retraining)
Number of subjects: 96

Group type: COMPARATOR
Intervention: ST+Sham (cognitive-behavioral therapy for smoking cessation and sham retraining)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: ST+ABR
Number of subjects: 96

Group type: COMPARATOR
Intervention: ST+Sham
Number of subjects: 96
Study: 34280516

Group type: EXPERIMENTAL
Intervention: Genetically-predicted IL-6
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genetically-predicted sIL-2Rα
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genetically-predicted IL-9
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genetically-predicted BDNF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genetically-predicted MCP-1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CRP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bipolar disorder
Number of subjects: 0
Study: 36335478

Group type: EXPERIMENTAL
Intervention: Immediate VA-ECMO
Number of subjects: 117

Group type: COMPARATOR
Intervention: No immediate VA-ECMO
Number of subjects: 117
Study: 34013615

Group type: EXPERIMENTAL
Intervention: Green-light laser en bloc resection
Number of subjects: 233

Group type: COMPARATOR
Intervention: Transurethral resection of bladder tumor
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 233
Study: 32450182

Group type: EXPERIMENTAL
Intervention: Mitomycin C
Number of subjects: 142

Group type: COMPARATOR
Intervention: Lactobacillus plantarum and Lactobacillus rhamnosus strains
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: PHASTER software
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Genomic collinear analysis
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Lactobacillus brevis temperate phages
Number of subjects: 142
Study: 36111123

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEXL, DEXH)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Remifentanil (REML, REMH)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Propofol (PRO)
Number of subjects: 120
Study: 32353418

Group type: EXPERIMENTAL
Intervention: Dynamic assessments of fluid responsiveness (passive leg raise) before fluid bolus or vasopressor increase.
Number of subjects: 124

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 124
Study: 33305896

Group type: EXPERIMENTAL
Intervention: Nifedipine alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nifedipine combined with sildenafil citrate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33114210

Group type: EXPERIMENTAL
Intervention: Combination of Superoxide Dismutase, Alpha Lipoic Acid, Acetyl L-Carnitine, and Vitamin B12 for 12 months
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo for 12 months
Number of subjects: 85
Study: 35802816

Group type: EXPERIMENTAL
Intervention: Wearable tracker to monitor the number of steps taken per day
Number of subjects: 51
Study: 33893836

Group type: EXPERIMENTAL
Intervention: Double-poling (DP)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Diagonal-stride (DS)
Number of subjects: 23
Study: 36317412

Group type: EXPERIMENTAL
Intervention: Short message to increase self-efficacy via vicarious experiences, verbal persuasion and emotional arousal
Number of subjects: 497

Group type: COMPARATOR
Intervention: Control condition (no message)
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: Short message to increase self-efficacy
Number of subjects: 497
Study: 32693993

Group type: EXPERIMENTAL
Intervention: Formal advance care planning (ACP) program
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 200
Study: 32548864

Group type: EXPERIMENTAL
Intervention: N. sativa hydrogel (twice daily for 60 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo hydrogel (twice daily for 60 days)
Number of subjects: 60
Study: 615137391

Group type: EXPERIMENTAL
Intervention: Shared service schedule
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard 7 days on schedule
Number of subjects: 0
Study: 35240263

Group type: EXPERIMENTAL
Intervention: Whey protein (WP) 20 g at breakfast + 20 g at dinner
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo-maltodextrin (PL) 20 g at breakfast + 20 g at dinner
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Whey protein (WP)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo-maltodextrin (PL)
Number of subjects: 31
Study: 33258114

Group type: COMPARATOR
Intervention: lanadelumab total group
Number of subjects: 125

Group type: COMPARATOR
Intervention: lanadelumab 300 mg q2wks
Number of subjects: 125
Study: 32167001

Group type: EXPERIMENTAL
Intervention: D-alanine (60 mg/kg)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: D-serine
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 35461158

Group type: EXPERIMENTAL
Intervention: Tofacitinib (5 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Xeljanz® (5 mg)
Number of subjects: 32
Study: 34001952

Group type: EXPERIMENTAL
Intervention: Novel biomarkers of PCa tumors discovered through cross-cancer learning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cross-cancer learning approach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Validation of discovered biomarkers
Number of subjects: 0
Study: 32738878

Group type: EXPERIMENTAL
Intervention: Semi-Fowler's position
Number of subjects: 141

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 141
Study: 32929234

Group type: EXPERIMENTAL
Intervention: ACC inhibitor (pharmacologic inhibition of acetyl‐CoA carboxylase)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 35388465

Group type: EXPERIMENTAL
Intervention: FLAG-Ida
Number of subjects: 94

Group type: COMPARATOR
Intervention: DClo
Number of subjects: 94
Study: 33070170

Group type: EXPERIMENTAL
Intervention: Horticultural Therapy (HT) intervention over 6 months
Number of subjects: 59

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 59
Study: 32713326

Group type: EXPERIMENTAL
Intervention: Patient controlled analgesia pump
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Intermittent analgesia application
Number of subjects: 200
Study: 33723969

Group type: EXPERIMENTAL
Intervention: Prehabilitation group (n = 11) with home-based exercise, nutritional, and dietary advice delivered via smartwatch
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (n = 11) receiving usual care with smartwatch as placebo
Number of subjects: 22
Study: 32827226

Group type: EXPERIMENTAL
Intervention: Energy drink consumption
Number of subjects: 3688

Group type: EXPERIMENTAL
Intervention: Energy drink consumption frequency
Number of subjects: 3688

Group type: EXPERIMENTAL
Intervention: Age of first intake
Number of subjects: 3688

Group type: EXPERIMENTAL
Intervention: High consumption
Number of subjects: 3688

Group type: EXPERIMENTAL
Intervention: Reasons for consumption
Number of subjects: 3688
Study: 35785530

Group type: EXPERIMENTAL
Intervention: mRNA-1273 vaccine
Number of subjects: 700

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 viral copies at diagnosis
Number of subjects: 700
Study: 33445959

Group type: EXPERIMENTAL
Intervention: Interpersonal and Social Rhythm Therapy (IPSRT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IPSRT
Number of subjects: 0
Study: 33588758

Group type: EXPERIMENTAL
Intervention: Vildagliptin (50 mg once a day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no medication)
Number of subjects: 20
Study: 35575171

Group type: EXPERIMENTAL
Intervention: 10-week web-intervention (n=20)
Number of subjects: 41

Group type: COMPARATOR
Intervention: wait-list control (n=21)
Number of subjects: 41
Study: 33038079

Group type: EXPERIMENTAL
Intervention: Comarum palustre L. tablets 500 mg twice daily for 28 days
Number of subjects: 15
Study: 32142119

Group type: COMPARATOR
Intervention: Incident obesity at 43 years (vs never) in 1946-NSHD
Number of subjects: 11001

Group type: COMPARATOR
Intervention: Incident obesity at 53 years (vs never) in 1946-NSHD
Number of subjects: 11001

Group type: COMPARATOR
Intervention: Persistent obesity from 36 years in 1946-NSHD
Number of subjects: 11001

Group type: COMPARATOR
Intervention: Inactivity as a mediator for incident obesity at 43 years in 1946-NSHD
Number of subjects: 11001

Group type: COMPARATOR
Intervention: Inactivity as a mediator for incident obesity at 53 years in 1946-NSHD
Number of subjects: 11001

Group type: COMPARATOR
Intervention: Inactivity as a mediator for persistent obesity from 36 years in 1946-NSHD
Number of subjects: 11001

Group type: COMPARATOR
Intervention: Patterns of association in 1958-NCDS
Number of subjects: 11001
Study: 35066880

Group type: EXPERIMENTAL
Intervention: ADJ
Number of subjects: 1093

Group type: EXPERIMENTAL
Intervention: DEP
Number of subjects: 1093

Group type: COMPARATOR
Intervention: CONT
Number of subjects: 1093
Study: 34506964

Group type: EXPERIMENTAL
Intervention: Mouse allergen reduction
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Lower indoor PM10 levels
Number of subjects: 297

Group type: COMPARATOR
Intervention: Sensitization and exposure to other indoor allergens
Number of subjects: 297
Study: 33534226

Group type: EXPERIMENTAL
Intervention: Intravenous antibiotics only
Number of subjects: 186

Group type: COMPARATOR
Intervention: Appendectomy
Number of subjects: 186
Study: 32444407

Group type: EXPERIMENTAL
Intervention: Downhill walking training (DT)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Conventional training (CT)
Number of subjects: 35
Study: 34518652

Group type: EXPERIMENTAL
Intervention: Enzalutamide plus androgen deprivation therapy (ADT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus androgen deprivation therapy (ADT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33688697

Group type: EXPERIMENTAL
Intervention: Continuous video-EEG (cEEG, lasting hours to several days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine video-EEG (rEEG, lasting 20-30 min)
Number of subjects: 0
Study: 32887570

Group type: EXPERIMENTAL
Intervention: Sit-to-stand (STS) exercises combined with Oral Nutritional Supplements (ONS) intake
Number of subjects: 23
Study: 35621877

Group type: COMPARATOR
Intervention: No anti-HBV (Zidovudine + intrapartum nevirapine + 1 week of tenofovir disoproxil fumarate and emtricitabine)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: 3TC (3TC + Zidovudine + LPV/r)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: FTC-TDF (FTC + TDF + LPV/r)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: FTC-TDF
Number of subjects: 138

Group type: COMPARATOR
Intervention: No anti-HBV
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: 3TC
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Maternal HBeAg positive
Number of subjects: 138
Study: 34732197

Group type: EXPERIMENTAL
Intervention: On-X Mechanical Prosthesis
Number of subjects: 855

Group type: COMPARATOR
Intervention: St Jude Medical Mechanical Prosthesis
Number of subjects: 855

Group type: EXPERIMENTAL
Intervention: Western World Population
Number of subjects: 855

Group type: EXPERIMENTAL
Intervention: Developing World Population
Number of subjects: 855
Study: 33408261

Group type: EXPERIMENTAL
Intervention: Bandage
Number of subjects: 62

Group type: COMPARATOR
Intervention: Casting
Number of subjects: 62
Study: 36145090

Group type: EXPERIMENTAL
Intervention: Spirulina maxima 70% ethanol extract (SM70EE) 1 g/day
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 33097279

Group type: EXPERIMENTAL
Intervention: Vaccinated with live LaSota ND vaccine (CV)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Administered ND vaccine and 0.25 mg/kg body weight (BW) LPS (L‐LPS)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Administered ND vaccine and 0.5 mg/kg BW LPS (H‐LPS)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Normal control (NC)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: ND vaccination combined LPS
Number of subjects: 128
Study: 36252937

Group type: EXPERIMENTAL
Intervention: Enhanced Usual Care augmented with a culturally adapted version of Caring Contacts (12 months, 25 messages)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enhanced Usual Care (control)
Number of subjects: 0
Study: 33394904

Group type: EXPERIMENTAL
Intervention: Low-frequency rTMS with intensive speech therapy (ST)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 2 times a day low-frequency rTMS with intensive speech therapy (ST)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (intensive speech therapy only)
Number of subjects: 30
Study: 34618409

Group type: EXPERIMENTAL
Intervention: Intracavernosal injection (ICI) of 100 units of BoNT‐A in 2 ml of saline
Number of subjects: 70

Group type: COMPARATOR
Intervention: 2 ml of saline (control)
Number of subjects: 70
Study: 33389302

Group type: EXPERIMENTAL
Intervention: Driving Training Program (10 driving lessons with a professional driving instructor)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 72
Study: 32978449

Group type: EXPERIMENTAL
Intervention: 0.3-ppm ozone for two hours
Number of subjects: 17

Group type: COMPARATOR
Intervention: Clean air
Number of subjects: 17
Study: 35030410

Group type: EXPERIMENTAL
Intervention: Hybrid esophagectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open esophagectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline role functioning score increase by 10 points
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fatigue score increase by 10 points
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pain score increase by 10 points
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher pain score
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher insomnia score
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Esophageal adenocarcinoma diagnosis
Number of subjects: 0
Study: 33044793

Group type: EXPERIMENTAL
Intervention: Lenvatinib (12 mg orally once daily for patients with a baseline body weight ≥60 kg and 8 mg orally once daily for patients with a baseline body weight <60 kg)
Number of subjects: 954

Group type: COMPARATOR
Intervention: Sorafenib (400 mg orally twice daily)
Number of subjects: 954

Group type: EXPERIMENTAL
Intervention: Lenvatinib
Number of subjects: 954

Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 954
Study: 34708415

Group type: EXPERIMENTAL
Intervention: Interpersonal relational role analysis (IRRA)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 10
Study: 34530868

Group type: EXPERIMENTAL
Intervention: mHealth, CPN‐administered decision support intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 0
Study: 32447767

Group type: EXPERIMENTAL
Intervention: Jessner's solution (JS)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Salicylic acid (SA) 30%
Number of subjects: 36
Study: 35436290

Group type: EXPERIMENTAL
Intervention: T13‐Jeevamrut 16.08 L plant‐1 + Vermicompost 24.79 kg plant‐1
Number of subjects: 42
Study: 34376536

Group type: EXPERIMENTAL
Intervention: Early high-dose glucocorticoids (GCC) use (≥60mg prednisone equivalent qd) after irAE onset
Number of subjects: 947

Group type: EXPERIMENTAL
Intervention: Early high-dose GCC use
Number of subjects: 947

Group type: EXPERIMENTAL
Intervention: Accumulated GCC exposure
Number of subjects: 947

Group type: COMPARATOR
Intervention: Control group (irAE without early high-dose GCC use)
Number of subjects: 947
Study: 32326815

Group type: EXPERIMENTAL
Intervention: Three-stage caregiver support intervention (provided 5 days before transplant, 14 days after transplant, and 1 week before discharge)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Three-stage caregiver support intervention
Number of subjects: 45

Group type: COMPARATOR
Intervention: Standard support provided in the hospital ward (control group)
Number of subjects: 45
Study: 35768108

Group type: EXPERIMENTAL
Intervention: Changes to diet and/or physical activity (PA) as part of a factorial randomised controlled trial
Number of subjects: 17
Study: 33887514

Group type: EXPERIMENTAL
Intervention: D2 gastrectomy
Number of subjects: 267

Group type: COMPARATOR
Intervention: D1 gastrectomy
Number of subjects: 267
Study: 32058596

Group type: EXPERIMENTAL
Intervention: 6 g of octanoic acid‐rich MCT (OAR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 6 g of decanoic acid‐rich MCT (DAR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 6 g of MCT (OAR or DAR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0 g of MCT (control)
Number of subjects: 0
Study: 35395951

Group type: EXPERIMENTAL
Intervention: felzartamab (16 mg/kg per infusion)
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: felzartamab
Number of subjects: 20
Study: 33792490

Group type: EXPERIMENTAL
Intervention: Cancer patients
Number of subjects: 292

Group type: COMPARATOR
Intervention: Non-cancer patients
Number of subjects: 292
Study: 36463655

Group type: EXPERIMENTAL
Intervention: VR-based physical activity program (24 sessions, 40 min each, twice a week)
Number of subjects: 23
Study: 33226501

Group type: EXPERIMENTAL
Intervention: Medical treatment plus daily supplementation of oral probiotics (≥ 1 × 10^9 live cells of Streptococcus thermophilus ST10, ≥ 1 × 10^9 live cells of Lactococcus lactis LCC02, ≥ 1 × 10^9 live cells of Lactobacillus delbrueckii subsp. bulgaricus)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Medical treatment (lid hygiene, warm compression and dexamethasone/tobramycin ointment for at least 20 days)
Number of subjects: 26
Study: 35276963

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (4000 IU daily for 12 weeks)
Number of subjects: 530

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 530
Study: 34533466

Group type: EXPERIMENTAL
Intervention: App-based treatment for urinary incontinence
Number of subjects: 17
Study: 33509974

Group type: EXPERIMENTAL
Intervention: Oral ingestion of MSG
Number of subjects: 16

Group type: COMPARATOR
Intervention: Topical application (swishing) of MSG
Number of subjects: 16
Study: 32366156

Group type: EXPERIMENTAL
Intervention: FDC of empagliflozin 5 mg/linagliptin 2.5 mg/metformin XR 1000 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: FDC of empagliflozin 25 mg/linagliptin 5 mg/metformin XR 1000 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Free tablet combinations of empagliflozin/linagliptin/metformin XR
Number of subjects: 60
Study: 34864785

Group type: EXPERIMENTAL
Intervention: Sustained WHO risk drinking reductions of 2 or more levels throughout treatment
Number of subjects: 964

Group type: EXPERIMENTAL
Intervention: Reduction of exactly 1 level
Number of subjects: 964
Study: 34242837

Group type: EXPERIMENTAL
Intervention: adaptive dual n-back training
Number of subjects: 60

Group type: COMPARATOR
Intervention: non-adaptive 1-back training
Number of subjects: 60
Study: 32997744

Group type: EXPERIMENTAL
Intervention: Immediate isoniazid preventive therapy (IPT) during pregnancy
Number of subjects: 925
Study: 32841554

Group type: EXPERIMENTAL
Intervention: Aripiprazole Lauroxil 441 mg every 4 weeks
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: Aripiprazole Lauroxil 882 mg every 4 weeks
Number of subjects: 478
Study: 33820572

Group type: EXPERIMENTAL
Intervention: Vitamin A (600 μg RAE/d)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Vitamin D (10 μg/d)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Combination of Vitamin A (600 μg RAE/d) and Vitamin D (10 μg/d)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Standard anti-tuberculosis treatment alone (Control group)
Number of subjects: 279